Autoimmune bullous disease
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: #1 Diagnosed as pemphigus group or pemphigus group. #2 Those not planning treatment with steroid pulse therapy or IVIG therapy. #3 The age at the time of consent acquisition is over 20 years old. #4 The latest blood test and liver function test within 4 weeks before registration satisfy all of the following. Number of neutrophils >= 1,500 / mm3 Platelet count >= 75,000 / mm3 AST (GOT) <120 IU / L ALT (GPT) <120 IU / L Total bilirubin <1.8 mg / dL 5) In the case of men, those agreeing to contrace up to 4 weeks after the start of the study drug administration from the date of final administration of the test drug. In the case of women, one after surgical contraceptive surgery such as postmenopausal (more than 1 year since the last menstruation), or bilateral oophorectomy. 6) With regard to participation in this study, written informed consent has been obtained from the patient himself.
Exclusion criteria
Exclusion criteria: 1) There is a history that has allergy to Imatinib. 2) It has one of the following complications. Serious heart disease or its past liver disorder, renal disorder 3) Consent Acknowledging participation in other exams within 4 weeks before acquisition. 4) In addition, patients judged unsuitable for the trial responsible doctor or shared medical doctor to safely carry out this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Improvement of severity of autoimmune bullous disease | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in autoantibody titer in blood Changes in antibody titer in body fluid (saliva, content of blisters) | — |
Countries
Japan
Contacts
Kyoto University Hospital Department of Dermatology